Treatment of ankylosing spondylitis with co-amoxiclav.

This article presents the efficacy of co-amoxiclav in two patients with ankylosing spondylitis. Both patients were administered oral co-amoxiclav for 7 days. The primary efficacy variable was the ankylosing spondylitis activity index. Secondary outcome measures were the ankylosing spondylitis functional index and spinal mobility. We detected a marked improvement in all symptoms and physical examination parameters. Co-amoxiclav has been shown to be effective against ankylosing spondylitis.